Recent Updates
Recently added Catalysts
ALGS Positive Sentiment

Class A capsid assembly modulator RG7907 clears HBV-infected hepatocytes through core-dependent hepatocyte death and proliferation

Tuesday, October 3, 2023 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: The article discusses RG7907, a Class A capsid assembly modulator, which has demonstrated efficacy in clearing HBV-infected hepatocytes. The treatment operates through a mechanism that involves core-dependent hepatocyte death and subsequent proliferation. This development may open new pathways for treating chronic HBV infections.
Price reaction · baseline $20 (2023-10-02 close) · hit pre-market · clean, no other ALGS news in the window
day 0 close
0%

Market Sentiment Analysis

POSITIVE FACTORS

  • RG7907 shows potential in clearing HBV-infected hepatocytes.
  • The mechanism involves core-dependent hepatocyte death and proliferation.
  • This could lead to new treatment avenues for chronic HBV infection.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+153%
120-day peak, hindsight
Typical move
6.1%
average across 6 past catalysts
Cash runway
~3 mo
High dilution risk
Lead asset
ALG-055009
Phase 2 · NASH

Full Press Release Details

• About Overview Management Board of Directors
• Science Pipeline Posters & Presentations
• Patients Chronic HBV Infection MASH Clinical Trials Expanded Access Policy
• News & Media Press Releases Presentations & Events
• Investors Overview Stock Stock Quote & Chart Analyst Coverage News & Events News Releases Investor Calendar Financials SEC Filings Quarterly Results Governance Governance Highlights Committee Composition Resources Investor FAQs Email Alerts Contact IR
• Careers
• Overview
• Management
• Board of Directors
• Pipeline
• Posters & Presentations
• Chronic HBV Infection
• MASH
• Clinical Trials
• Expanded Access Policy
• Press Releases
• Presentations & Events
• Overview
• Stock Stock Quote & Chart Analyst Coverage
• News & Events News Releases Investor Calendar
• Financials SEC Filings Quarterly Results
• Governance Governance Highlights Committee Composition
• Resources Investor FAQs Email Alerts Contact IR
• Stock Quote & Chart
• Analyst Coverage
• News Releases
• Investor Calendar
• SEC Filings
• Quarterly Results
• Governance Highlights
• Committee Composition
• Investor FAQs
• Email Alerts
• Contact IR

Frequently Asked Questions

What is RG7907?

RG7907 is a Class A capsid assembly modulator aimed at treating HBV.

How does RG7907 work?

It clears HBV-infected hepatocytes through core-dependent death and proliferation.

What is the significance of RG7907?

It may provide new treatment options for chronic HBV infections.

ShareAdd on Google
Tags: ALGS Viatris Investor Conferences Healthcare RG7907 HBV hepatocytes chronic HBV infection capsid assembly modulator
Last updated: Oct 3, 2023

Biotech snapshot

Cash runway
$30M liquidity · $8M/mo burn
~3 mo
High dilution risk
Lead asset
ALG-055009Phase 2
NASH →

Catalyst track record

+153%
best trade around ALGS's most recent catalyst

Peak hindsight return over a 120-day window, across 6 tracked FDA/PDUFA catalysts for ALGS.

See every catalyst's timing & PoA →